Navigation Links
Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
Date:8/14/2008

CRANBURY, N.J., Aug. 14 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (Amex: PTN) announced today the completion of a Phase 2a clinical trial of PL-3994, a novel, long-acting natriuretic peptide receptor A (NPRA) agonist under development for treatment of heart failure (HF). The Phase 2a trial was a randomized, double-blind, placebo-controlled, single ascending dose study in 21 volunteers with controlled hypertension who received the medication or placebo subcutaneously. The purpose of the study was to demonstrate that PL-3994 can be given safely to patients taking antihypertensive medications commonly administered to heart failure and hypertension patients. The evaluations included safety, tolerability, pharmacokinetics and several pharmacodynamic endpoints, including levels of cyclic guanosine monophosphate (cGMP), a natural messenger nucleotide.

Dosing concluded with the successful achievement of the primary endpoint of the study, a pre-specified reduction in systemic blood pressure. No volunteer experienced a serious or severe adverse event. Elevations in plasma cGMP levels were all observed for several hours after single subcutaneous doses. Additional data analysis is ongoing and will be submitted for presentation when the analysis is complete.

"We are excited to confirm that PL-3994 can be given safely to patients who are taking blood pressure medications," stated Dr. Trevor Hallam, Palatin's Executive Vice President for Research and Development. "As we proceed with an additional Phase 2 study later this year, we will focus on the heart failure patients most in need of new therapies."

The previously announced Phase 1 study demonstrated that PL-3994 can be given safely and leads to a dose-related decrease i
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Palatin Technologies Announces Reacquisition of Full Rights to Bremelanotide Program
2. Palatin Technologies Refutes Competitive Technologies Contention of Material Breach
3. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2007 Results; Teleconference and Webcast to be held on September 18, 2007
4. Palatin Technologies to Report Fiscal Year 2008 First Quarter Results; Teleconference and Webcast on November 9, 2007
5. Palatin Technologies, Inc. Reports Fiscal Year 2008 First Quarter Results; Teleconference and Webcast to be Held on November 9, 2007
6. Palatin Technologies to Report Second Quarter, Fiscal Year 2008 Financial Results; Teleconference and Webcast on February 11th
7. Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure
8. Palatin Technologies to Report Third Quarter, Fiscal Year 2008 Financial Results; Teleconference and Webcast on May 13th
9. Palatin Technologies Announces New Strategic Objectives and Reports Third Quarter 2008 Financial Results
10. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
11. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... (PRWEB) July 25, 2014 At the ... has granted a 60-day extension for the public comment ... Special Rule for Model Aircraft established by Congress as ... 2012. The 60-day extension establishes the new deadline for ... States Department of Transportation/FAA notice published in the Federal ...
(Date:7/24/2014)... -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced the ... Phase 3 study of Zerenex (ferric citrate), the Company,s ... of hyperphosphatemia in patients with end-stage renal disease (ESRD) ... delivery with FErric CiTrate in EsrD) was published online ... of Nephrology ( JASN ). , ...
(Date:7/24/2014)... July 24, 2014 Gain recognition ... Supply Chain of the biotech industry. Nominations are ... Awards, brought to you by the Bio ... of supply chain management professionals for the past ... stakeholders of the Biotech industry – Manufacturers, Service ...
(Date:7/24/2014)... , July 24, 2014  Asterias Biotherapeutics, Inc. ... emerging field of regenerative medicine, announced today that ... presentation to investors on Tuesday, July 29, 2014, ... presentation will include an overview of Asterias, business ... webcast, visit http://www.ustream.tv/channel/asterias-biotherapeutics at least 15 ...
Breaking Biology Technology:FAA Grants Comment Extension at the Request of AMA 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4Call for Submission: BSMA’s Supply Chain Management Innovation Awards 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 3Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4
... NEW ORLEANS, and RESEARCH TRIANGLE PARK, N.C., Nov. ... presented in vitro data demonstrating that ... not substrates for the human Organic Anion Transporters ... cause nephrotoxicity via this mechanism.  These data, presented ...
... Health Invites Medisafe 1 Technologies to Demonstrate its... -- JERUSALEM, November 16, 2010 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so we ...
... SHENYANG, China, Nov. 15, 2010 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. ... a leading China-based biotechnology company focused on researching, developing, ... financial results for the third quarter ended September 30, ... Highlights: Total net revenues increased ...
Cached Biology Technology:Chimerix's PIM Conjugate Technology Reduces Risk of Nephrotoxicity for CMX001 and CMX157 2Chimerix's PIM Conjugate Technology Reduces Risk of Nephrotoxicity for CMX001 and CMX157 3Chimerix's PIM Conjugate Technology Reduces Risk of Nephrotoxicity for CMX001 and CMX157 4The Israeli Government's Ministry of Health Invites Medisafe 1 Technologies to Demonstrate its Unique Syringe Locking Device Technology 2The Israeli Government's Ministry of Health Invites Medisafe 1 Technologies to Demonstrate its Unique Syringe Locking Device Technology 3The Israeli Government's Ministry of Health Invites Medisafe 1 Technologies to Demonstrate its Unique Syringe Locking Device Technology 4The Israeli Government's Ministry of Health Invites Medisafe 1 Technologies to Demonstrate its Unique Syringe Locking Device Technology 5The Israeli Government's Ministry of Health Invites Medisafe 1 Technologies to Demonstrate its Unique Syringe Locking Device Technology 6The Israeli Government's Ministry of Health Invites Medisafe 1 Technologies to Demonstrate its Unique Syringe Locking Device Technology 7The Israeli Government's Ministry of Health Invites Medisafe 1 Technologies to Demonstrate its Unique Syringe Locking Device Technology 83SBio Inc. Announces Unaudited Third Quarter Results 23SBio Inc. Announces Unaudited Third Quarter Results 33SBio Inc. Announces Unaudited Third Quarter Results 43SBio Inc. Announces Unaudited Third Quarter Results 53SBio Inc. Announces Unaudited Third Quarter Results 63SBio Inc. Announces Unaudited Third Quarter Results 73SBio Inc. Announces Unaudited Third Quarter Results 83SBio Inc. Announces Unaudited Third Quarter Results 93SBio Inc. Announces Unaudited Third Quarter Results 103SBio Inc. Announces Unaudited Third Quarter Results 113SBio Inc. Announces Unaudited Third Quarter Results 123SBio Inc. Announces Unaudited Third Quarter Results 133SBio Inc. Announces Unaudited Third Quarter Results 143SBio Inc. Announces Unaudited Third Quarter Results 153SBio Inc. Announces Unaudited Third Quarter Results 163SBio Inc. Announces Unaudited Third Quarter Results 173SBio Inc. Announces Unaudited Third Quarter Results 18
(Date:7/24/2014)... where electric cars ply silent freeways, solar panels blanket ... the earth, from howling winds and from the blazing ... it is technically and economically feasible to convert California,s ... energy. Published in Energy , the plan shows ... supply in California that could create tens of thousands ...
(Date:7/24/2014)... has its own microbial terroir, meaning the microbial populations ... in the product, creating the final flavor according to ... Applied and Environmental Microbiology . This is the first ... sake brewery. , Many sake makers inoculate with ... Mills of the University of California, Davis, but he ...
(Date:7/24/2014)... O.D., a low vision specialist at The University of ... has been awarded a grant to help Harris County ... medication or surgery. , Even with corrective lenses, many ... However, there are a variety of low vision devices, ... offset their vision loss. , Iyer is using the ...
Breaking Biology News(10 mins):Stanford study shows how to power California with wind, water and sun 2Stanford study shows how to power California with wind, water and sun 3Stanford study shows how to power California with wind, water and sun 4The microbes make the sake brewery 2UTHealth Dr. Bhavani Iyer awarded low vision grant 2
... with millions of enamel-eroding, gum-inflaming microbes. , One of ... a claim deep within the spaces between teeth and ... ?secreting proteins that destroy the soft tissues and bone ... scientists have identified the thousands of proteins the bacterium ...
... of arboreal animals have learned to glide through the ... and even ?frightening as it sounds ?snakes. , Now, ... University of California, Berkeley, and the University of Texas ... only wingless insects known to actively direct their fall ...
... into ribonucleic acids (RNA)--the building blocks of life--is exploding ... genetics, health, disease and the development of organisms. The ... for researchers to develop a shared vocabulary and system ... international team of RNA scientists, known as the RNA ...
Cached Biology News:UF Researchers Map Bacterial Proteins That Cause Tooth Loss 2UF Researchers Map Bacterial Proteins That Cause Tooth Loss 3Falling ants glide back to trunk to avoid dangers of forest floor 2Falling ants glide back to trunk to avoid dangers of forest floor 3Falling ants glide back to trunk to avoid dangers of forest floor 4Falling ants glide back to trunk to avoid dangers of forest floor 5RNA project to create language for scientists worldwide 2RNA project to create language for scientists worldwide 3
Bovine Serum Albumin Heat Shock Diagnostic Grade Powder...
MpV17 transgene, murine homolog, glomerulosclerosis...
... the premium quality siRNAs you need for ... be readily ordered online by providing either ... providing the sense and antisense siRNA sequences. ... Silencer Pre-designed siRNAs, which are already designed ...
Human SDNSF/MCFD2 Biotinylated Affinity Purified PAb...
Biology Products: